GSK Is Maintained at Buy by Jefferies

GSK Is Maintained at Buy by Jefferies

Dow Jones02:09

Jefferies Maintains Buy on GSK, Raises Price Target to $53

Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.

Benzinga01:58

GSK Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 39.51% Jefferies $52.5 → $53 Maintains Buy 05/30/2024 23.72% Goldman Sachs → $47 Initiates Cove

Benzinga01:53

Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices

Seeking AlphaJul 2 21:17

Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims

A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer

BenzingaJul 2 20:39

Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $53

Jefferies analyst Peter Welford maintains $GlaxoSmithKline(GSK.US)$ with a buy rating, and adjusts the target price from $28.48 to $53.According to TipRanks data, the analyst has a success rate of 52.

Futu NewsJul 2 18:31 · Ratings